Related Experiment Videos
[Effects of OK-432 on UFT activation]
11st Dept of Surgery, Yokohama City Univ. School of Med.
Gan No Rinsho. Japan Journal of Cancer Clinics
|May 1, 1988
Summary
The immunomodulator OK-432 shows minimal impact on the activation of UFT (uracil and tegafur) when administered together. Studies found no significant differences in 5-FU concentrations in blood or tumors, suggesting limited interaction between these cancer therapies.
Area of Science:
- Pharmacology
- Cancer Therapy
- Immunomodulation